“The world is looking at PolycapTM, developed by Cadila Pharmaceuticals Ltd. We promise more such
firsts-in-the-world in times to come.”
– Shri I.A. Modi, Chairman
- Research reveals PolycapTM reduced the risk of Coronary Heart Disease by 62% and Stroke by 48%
- Findings were published in The Lancet, a refereed journal
- The results were shared with thousands of Cardiologists at the Cardiology College’s Conference in Florida
“All over the world, response to the research findings on Polycap is overwhelming.
This is a proud moment for me as an Indian that an Indian Pharmaceutical company has worked hard to achieve this feat” said Shri I A Modi, Chairman of Cadila Pharmaceuticals, Ahmedabad while sharing the results of TIPS Study with media.
According to “The Indian Polycap Study (TIPS)” published in the latest edition of The Lancet, PolycapTM has shown to bring down the risk of coronary heart disease by 62% and stroke by 48%. Cardiovascular diseases, predominantly heart disease and stroke account for around 30% of all deaths around the world.
According to Shri Modi, “A typical patient of heart diseases needs to take more than 5-6 pills of different medications everyday for lifelong, putting immense burden of not only the illness but the treatment itself and has a negative effect on the quality of life of the individual.” The Polycap will also offer a big psychological advantage to patients. He further said that “there is no drug currently available which can be taken by individuals who are at high risk for these illnesses as a means of primary prevention”.
Elaborating on the composition and trials of Polycap, Shri Modi said that “PolycapTM, is a combination of 3 common antihypertensive drugs along with aspirin and a statin (cholesterol lowering drug). PolycapTM has been tested in over 2000 patients across 50 centers in India by one of the most respected clinical researchers Dr Salim Yusuf from McMaster University Canada”
According to the study published in The Lancet, “PolycapTM reduced multiple risk factors for cardiovascular diseases such as lowering the blood pressure, the heart rate, the lipids and decreasing the stickiness of the platelets”.
Participants had an average age of 54 years, with at least one risk factor for heart disease - high blood pressure, high cholesterol, obesity, diabetes or smoking. Compared to groups given no blood pressure medicines, those who got the polypill lowered their systolic blood pressure (the top number) by more than 7 units and their diastolic (the bottom number) by about 6 - comparable to levels for people who were given the three drugs without aspirin and the cholesterol drug.
LDL, or bad cholesterol, dropped 23 percent on the polypill versus 28 percent in those taking the statin drug separately. Triglycerides dropped 10 percent on the combo pill versus 20 percent with individual statin use. Neither pill affected levels of HDL, or good cholesterol. Anti-clotting effects seemed the same with the polypill as with aspirin alone. Side effect rates were the same for the polypill as for the five medicines individually.
“Formulating a single pill of five drugs that work in five different ways is a complex task - more complex than simply mixing the medicines. Pills have coatings and other ingredients that control the rate at which the medicine is released into the bloodstream. This also represents our R&D capabilities in Formulations Development” said Shri Modi.